-2%
Utromeg tablet is indicated for the symptomatic treatment of urgency, increased micturition frequency, and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.
Doses up to 400 mg have been tested in healthy individuals, leading to increased pulse and palpitations. Prolonged dosing at 300 mg may cause elevated heart rate and blood pressure. In case of overdose, supportive care with monitoring of heart rate, blood pressure, and ECG is essential.
Mirabegron is the first medication in its class, known as beta-3 adrenergic receptor agonists. It provides relief from overactive bladder symptoms by working through a dual mechanism. It not only directly relaxes the smooth muscles of the bladder but also influences the sensory nervous system. By stimulating beta-3 receptors, Mirabegron increases the concentration of cyclic adenosine monophosphate (cAMP), promoting relaxation of the detrusor muscle during the bladder’s storage phase, thereby increasing its urine-holding capacity. Utromeg 25 works by relaxing the muscles around your bladder during the storage phase of the urinary bladder fill-void cycle, which increases the bladder’s capacity to hold more urine, thereby reducing the feelings of urgency and the need to urinate frequently.